TABLE 1.
Patient demographics for each diplotype
| Phenotype | Genotype | Patients, n (%) | Samples, n | Women, n (%) | Age, years, mean (SD) | Drug dosage, mg/day, mean (SD) | Time between last drug intake and blood sampling (h), mean (SD) |
|---|---|---|---|---|---|---|---|
| UM | CYP2C19*17/CYP2C19*17 | 44 (5.2) | 89 | 31 (70.5) | 41.3 (17.2) | 115.5 (60.2) | 20.3 (5.75) |
| CYP2C:TG/CYP2C:TG | 26 (3.1) | 34 | 14 (53.9) | 45.2 (20.0) | 97.1 (35.8) | 21.1 (4.54) | |
| CYP2C:TG/CYP2C19*17 | 65 (7.7) | 108 | 43 (66.2) | 51.1 (19.7) | 120.7 (71.0) | 21.0 (5.64) | |
| RM | CYP2C19*1/CYP2C19*17 | 150 (17.9%) | 286 | 103 (68.7) | 45.8 (18.1) | 145.0 (126.0) | 19.9 (5.31) |
| CYP2C19*1/CYP2C:TG | 142 (16.9) | 222 | 95 (66.9) | 44.2 (17.9) | 111.6 (53.3) | 20.4 (5.21) | |
| NM | CYP2C19*1/CYP2C19*1 (Ref.) | 160 (19.1) | 288 | 99 (61.9) | 44.2 (18.6) | 106.3 (51.4) | 20.2 (5.68) |
| IM | CYP2C19*17/CYP2C19 Null | 55 (6.6) | 93 | 33 (60.0) | 46.4 (18.4) | 113.6 (57.5) | 20.0 (5.74) |
| CYP2C:TG/CYP2C19 Null | 61 (7.3) | 120 | 41 (67.2) | 43.9 (18.7) | 98.0 (48.4) | 18.7 (5.69) | |
| CYP2C19*1/CYP2C19 Null | 108 (12.9) | 167 | 69 (63.9) | 44.9 (18.5) | 100.8 (53.0) | 21.4 (5.10) | |
| PM | CYP2C19 Null/CYP2C19 Null | 29 (3.5) | 75 | 21 (72.4) | 34.0 (14.3) | 110.5 (47.3) | 18.9 (5.46) |
| Total | 840 | 1482 | 549 (65.4) | 44.6 (18.4) | 115.3 (75.3) | 20.2 (5.48) | |
| UM | CYP2B6*1/*4 | 33 (4.2) | 62 | 21 (63.6) | 42.1 (16.0) | 117.3 (61.2) | 20.7 (6.04) |
| CYP2B6*4/*4 | 4 (0.5) | 8 | 3 (75.0) | 63.8 (21.8) | 150.0 (46.3) | 18.3 (5.80) | |
| NM | CYP2B6*1/*1 (Ref.) | 454 (57.3) | 848 | 297 (65.4) | 43.8 (17.9) | 121.7 (87.2) | 20.1 (5.41) |
| IM | CYP2B6*1/*6 | 251 (31.7) | 383 | 162 (64.5) | 42.7 (18.3) | 106.1 (50.9) | 20.5 (5.54) |
| CYP2B6*1/*9 | 3 (0.4) | 7 | 3 (100) | 45.3 (11.2) | 132.1 (23.8) | 24.2 (1.36) | |
| CYP2B6*4/*6 | 7 (0.9) | 13 | 5 (71.4) | 54.5 (22.8) | 107.7 (78.7) | 19.4 (5.90) | |
| PM | CYP2B6*6/*6 | 39 (4.9) | 46 | 24 (61.5) | 45.7 (19.6) | 87.0 (52.2) a | 20.3 (5.47) |
| CYP2B6*9/*9 | 1 (0.1) | 2 | 1 (100) | 63.5 (0.7) | 100.0 (0) | 23.4 (0.14) | |
| Total | 792 | 1369 | 516 (65.2) | 43.7 (18.1) | 116.0 (76.5) | 20.2 (5.48) |
Note: Null = no function allele (i.e., the presence of CYP2C19*2, CYP2C19*3, or CYP2C19*4). Ref. = reference genotype.
Abbreviations: IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.
a
Indicates significant difference (p < 0.05) compared with patients with the reference genotype (CYP2C19*1/*1 or CYP2B6*1/*1), patients not carrying any of the investigated variants.